CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: A prospective evaluation of 95 patients/118 lesions

B. A. Jereczek-Fossa, I. Bossi-Zanetti, R. Mauro, G. Beltramo, L. Fariselli, L. C. Bianchi, C. Fodor, P. Fossati, G. Baroni, R. Orecchia

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients. Patients and methods: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40 % of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST. Results: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17 %), 25 (29 %), 34 (39 %) and 13 (15 %) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2 %, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field. Conclusion: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.

Original languageEnglish
Pages (from-to)448-455
Number of pages8
JournalStrahlentherapie und Onkologie
Volume189
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Image-Guided Radiotherapy
Robotics
Neoplasms
Disease-Free Survival
Radiotherapy
Therapeutics
Survival Rate
Radiation Oncology
Comorbidity
Prostatic Neoplasms
Breast
Neck
Head
Organizations
Recurrence
Lung
Survival

Keywords

  • Computed tomography
  • Metastasis
  • Positron-emission tomography
  • Survival
  • Toxicity

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer : A prospective evaluation of 95 patients/118 lesions. / Jereczek-Fossa, B. A.; Bossi-Zanetti, I.; Mauro, R.; Beltramo, G.; Fariselli, L.; Bianchi, L. C.; Fodor, C.; Fossati, P.; Baroni, G.; Orecchia, R.

In: Strahlentherapie und Onkologie, Vol. 189, No. 6, 06.2013, p. 448-455.

Research output: Contribution to journalArticle

@article{c07109bd44824677830d17d5a4902e0b,
title = "CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: A prospective evaluation of 95 patients/118 lesions",
abstract = "Purpose: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients. Patients and methods: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40 {\%} of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST. Results: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17 {\%}), 25 (29 {\%}), 34 (39 {\%}) and 13 (15 {\%}) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2 {\%}, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field. Conclusion: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.",
keywords = "Computed tomography, Metastasis, Positron-emission tomography, Survival, Toxicity",
author = "Jereczek-Fossa, {B. A.} and I. Bossi-Zanetti and R. Mauro and G. Beltramo and L. Fariselli and Bianchi, {L. C.} and C. Fodor and P. Fossati and G. Baroni and R. Orecchia",
year = "2013",
month = "6",
doi = "10.1007/s00066-013-0345-y",
language = "English",
volume = "189",
pages = "448--455",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "6",

}

TY - JOUR

T1 - CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer

T2 - A prospective evaluation of 95 patients/118 lesions

AU - Jereczek-Fossa, B. A.

AU - Bossi-Zanetti, I.

AU - Mauro, R.

AU - Beltramo, G.

AU - Fariselli, L.

AU - Bianchi, L. C.

AU - Fodor, C.

AU - Fossati, P.

AU - Baroni, G.

AU - Orecchia, R.

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients. Patients and methods: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40 % of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST. Results: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17 %), 25 (29 %), 34 (39 %) and 13 (15 %) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2 %, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field. Conclusion: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.

AB - Purpose: To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients. Patients and methods: Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40 % of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST. Results: Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17 %), 25 (29 %), 34 (39 %) and 13 (15 %) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2 %, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field. Conclusion: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.

KW - Computed tomography

KW - Metastasis

KW - Positron-emission tomography

KW - Survival

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84878325562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878325562&partnerID=8YFLogxK

U2 - 10.1007/s00066-013-0345-y

DO - 10.1007/s00066-013-0345-y

M3 - Article

C2 - 23604189

AN - SCOPUS:84878325562

VL - 189

SP - 448

EP - 455

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 6

ER -